Efficacy and safety of sofosbuvir plus ribavirin for Korean patients with hepatitis C virus genotype 2 infection: A retrospective multi-institutional study
Background/Aims Sofosbuvir plus ribavirin is a standard treatment for patients infected with chronic hepatitis C virus (HCV) genotype 2 in Korea. The purpose of this study was to examine the efficacy and safety of this treatment in Korean patients with chronic HCV genotype 2 infection. Methods We re...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Korean Association for the Study of the Liver
2018-09-01
|
| Series: | Clinical and Molecular Hepatology |
| Subjects: | |
| Online Access: | http://e-cmh.org/upload/pdf/cmh-2017-0070.pdf |
| _version_ | 1818693635275751424 |
|---|---|
| author | Young Min Kim Suk Bae Kim Il Han Song Sae Hwan Lee Hong Soo Kim Tae Hee Lee Young Woo Kang Seok Hyun Kim Byung Seok Lee Hee Bok Chae Myeong Jun Song Ji Woong Jang Soon Young Ko Jae Dong Lee |
| author_facet | Young Min Kim Suk Bae Kim Il Han Song Sae Hwan Lee Hong Soo Kim Tae Hee Lee Young Woo Kang Seok Hyun Kim Byung Seok Lee Hee Bok Chae Myeong Jun Song Ji Woong Jang Soon Young Ko Jae Dong Lee |
| author_sort | Young Min Kim |
| collection | DOAJ |
| description | Background/Aims Sofosbuvir plus ribavirin is a standard treatment for patients infected with chronic hepatitis C virus (HCV) genotype 2 in Korea. The purpose of this study was to examine the efficacy and safety of this treatment in Korean patients with chronic HCV genotype 2 infection. Methods We retrospectively analyzed clinical data of patients treated with sofosbuvir plus ribavirin for chronic HCV genotype 2 from May 2016 to December 2017 at eight hospitals located in the Daejeon-Chungcheong area. Results A total of 172 patients were treated with sofosbuvir plus ribavirin. Of them, 163 patients completed the treatment, and 162 patients were tested for sustained virologic response 12 weeks after treatment discontinuation (SVR12). Mean age was 59.6±12.3 years (27–96), and 105 (64.4%) patients were female. Of the total patients, 49 (30.1%) were diagnosed with cirrhosis, and 31 of them were treated for 16 weeks. Sofosbuvir plus ribavirin was the first-line treatment for 144 (88.3%) patients. Eleven (6.7%) patients were intolerant to previous interferon-based treatment. Eight (5.0%) patients relapsed after interferon-based treatment. HCV RNA non-detection rate at 4, 8, and 12 weeks was 97.5%, 99.1%, and 99.3%, respectively, and SVR12 was 98.8% (161/163). During treatment, 18 (11.0%) patients had to reduce their administrated dose of ribavirin because of anemia. One patient stopped the treatment because of severe anemia. Other adverse events, including dizziness, indigestion, and headache, were found in 26 (16.0%) patients. Conclusions A 12-16 week treatment with sofosbuvir plus ribavirin is remarkably effective and well tolerated in Korean patients with chronic HCV genotype 2 infection. |
| first_indexed | 2024-12-17T13:16:49Z |
| format | Article |
| id | doaj.art-5a9ce1fbbb1e4e60850396f9de88913d |
| institution | Directory Open Access Journal |
| issn | 2287-2728 2287-285X |
| language | English |
| last_indexed | 2024-12-17T13:16:49Z |
| publishDate | 2018-09-01 |
| publisher | Korean Association for the Study of the Liver |
| record_format | Article |
| series | Clinical and Molecular Hepatology |
| spelling | doaj.art-5a9ce1fbbb1e4e60850396f9de88913d2022-12-21T21:46:59ZengKorean Association for the Study of the LiverClinical and Molecular Hepatology2287-27282287-285X2018-09-0124331131810.3350/cmh.2017.00701411Efficacy and safety of sofosbuvir plus ribavirin for Korean patients with hepatitis C virus genotype 2 infection: A retrospective multi-institutional studyYoung Min Kim0Suk Bae Kim1Il Han Song2Sae Hwan Lee3Hong Soo Kim4Tae Hee Lee5Young Woo Kang6Seok Hyun Kim7Byung Seok Lee8Hee Bok Chae9Myeong Jun Song10Ji Woong Jang11Soon Young Ko12Jae Dong Lee13 Department of Internal Medicine, Dankook University College of Medicine, Cheonan, Korea Department of Internal Medicine, Dankook University College of Medicine, Cheonan, Korea Department of Internal Medicine, Dankook University College of Medicine, Cheonan, Korea Department of Internal Medicine, Soonchunhyang University College of Medicine, Cheonan, Korea Department of Internal Medicine, Soonchunhyang University College of Medicine, Cheonan, Korea Department of Internal Medicine, Konyang University College of Medicine, Daejeon, Korea Department of Internal Medicine, Konyang University College of Medicine, Daejeon, Korea Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon, Korea Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon, Korea Department of Internal Medicine, Chungbuk National University College of Medicine, Cheongju, Korea Department of Internal Medicine, College of Medicine, Catholic University of Korea, Daejeon, Korea Department of Internal Medicine, Eulji University Hospital, Daejeon, Korea Department of Internal Medicine, Konkuk University School of Medicine, Chungju, Korea Department of Internal Medicine, Konkuk University School of Medicine, Chungju, KoreaBackground/Aims Sofosbuvir plus ribavirin is a standard treatment for patients infected with chronic hepatitis C virus (HCV) genotype 2 in Korea. The purpose of this study was to examine the efficacy and safety of this treatment in Korean patients with chronic HCV genotype 2 infection. Methods We retrospectively analyzed clinical data of patients treated with sofosbuvir plus ribavirin for chronic HCV genotype 2 from May 2016 to December 2017 at eight hospitals located in the Daejeon-Chungcheong area. Results A total of 172 patients were treated with sofosbuvir plus ribavirin. Of them, 163 patients completed the treatment, and 162 patients were tested for sustained virologic response 12 weeks after treatment discontinuation (SVR12). Mean age was 59.6±12.3 years (27–96), and 105 (64.4%) patients were female. Of the total patients, 49 (30.1%) were diagnosed with cirrhosis, and 31 of them were treated for 16 weeks. Sofosbuvir plus ribavirin was the first-line treatment for 144 (88.3%) patients. Eleven (6.7%) patients were intolerant to previous interferon-based treatment. Eight (5.0%) patients relapsed after interferon-based treatment. HCV RNA non-detection rate at 4, 8, and 12 weeks was 97.5%, 99.1%, and 99.3%, respectively, and SVR12 was 98.8% (161/163). During treatment, 18 (11.0%) patients had to reduce their administrated dose of ribavirin because of anemia. One patient stopped the treatment because of severe anemia. Other adverse events, including dizziness, indigestion, and headache, were found in 26 (16.0%) patients. Conclusions A 12-16 week treatment with sofosbuvir plus ribavirin is remarkably effective and well tolerated in Korean patients with chronic HCV genotype 2 infection.http://e-cmh.org/upload/pdf/cmh-2017-0070.pdfSofosbuvirRibavirinHepatitis C virusKorea |
| spellingShingle | Young Min Kim Suk Bae Kim Il Han Song Sae Hwan Lee Hong Soo Kim Tae Hee Lee Young Woo Kang Seok Hyun Kim Byung Seok Lee Hee Bok Chae Myeong Jun Song Ji Woong Jang Soon Young Ko Jae Dong Lee Efficacy and safety of sofosbuvir plus ribavirin for Korean patients with hepatitis C virus genotype 2 infection: A retrospective multi-institutional study Clinical and Molecular Hepatology Sofosbuvir Ribavirin Hepatitis C virus Korea |
| title | Efficacy and safety of sofosbuvir plus ribavirin for Korean patients with hepatitis C virus genotype 2 infection: A retrospective multi-institutional study |
| title_full | Efficacy and safety of sofosbuvir plus ribavirin for Korean patients with hepatitis C virus genotype 2 infection: A retrospective multi-institutional study |
| title_fullStr | Efficacy and safety of sofosbuvir plus ribavirin for Korean patients with hepatitis C virus genotype 2 infection: A retrospective multi-institutional study |
| title_full_unstemmed | Efficacy and safety of sofosbuvir plus ribavirin for Korean patients with hepatitis C virus genotype 2 infection: A retrospective multi-institutional study |
| title_short | Efficacy and safety of sofosbuvir plus ribavirin for Korean patients with hepatitis C virus genotype 2 infection: A retrospective multi-institutional study |
| title_sort | efficacy and safety of sofosbuvir plus ribavirin for korean patients with hepatitis c virus genotype 2 infection a retrospective multi institutional study |
| topic | Sofosbuvir Ribavirin Hepatitis C virus Korea |
| url | http://e-cmh.org/upload/pdf/cmh-2017-0070.pdf |
| work_keys_str_mv | AT youngminkim efficacyandsafetyofsofosbuvirplusribavirinforkoreanpatientswithhepatitiscvirusgenotype2infectionaretrospectivemultiinstitutionalstudy AT sukbaekim efficacyandsafetyofsofosbuvirplusribavirinforkoreanpatientswithhepatitiscvirusgenotype2infectionaretrospectivemultiinstitutionalstudy AT ilhansong efficacyandsafetyofsofosbuvirplusribavirinforkoreanpatientswithhepatitiscvirusgenotype2infectionaretrospectivemultiinstitutionalstudy AT saehwanlee efficacyandsafetyofsofosbuvirplusribavirinforkoreanpatientswithhepatitiscvirusgenotype2infectionaretrospectivemultiinstitutionalstudy AT hongsookim efficacyandsafetyofsofosbuvirplusribavirinforkoreanpatientswithhepatitiscvirusgenotype2infectionaretrospectivemultiinstitutionalstudy AT taeheelee efficacyandsafetyofsofosbuvirplusribavirinforkoreanpatientswithhepatitiscvirusgenotype2infectionaretrospectivemultiinstitutionalstudy AT youngwookang efficacyandsafetyofsofosbuvirplusribavirinforkoreanpatientswithhepatitiscvirusgenotype2infectionaretrospectivemultiinstitutionalstudy AT seokhyunkim efficacyandsafetyofsofosbuvirplusribavirinforkoreanpatientswithhepatitiscvirusgenotype2infectionaretrospectivemultiinstitutionalstudy AT byungseoklee efficacyandsafetyofsofosbuvirplusribavirinforkoreanpatientswithhepatitiscvirusgenotype2infectionaretrospectivemultiinstitutionalstudy AT heebokchae efficacyandsafetyofsofosbuvirplusribavirinforkoreanpatientswithhepatitiscvirusgenotype2infectionaretrospectivemultiinstitutionalstudy AT myeongjunsong efficacyandsafetyofsofosbuvirplusribavirinforkoreanpatientswithhepatitiscvirusgenotype2infectionaretrospectivemultiinstitutionalstudy AT jiwoongjang efficacyandsafetyofsofosbuvirplusribavirinforkoreanpatientswithhepatitiscvirusgenotype2infectionaretrospectivemultiinstitutionalstudy AT soonyoungko efficacyandsafetyofsofosbuvirplusribavirinforkoreanpatientswithhepatitiscvirusgenotype2infectionaretrospectivemultiinstitutionalstudy AT jaedonglee efficacyandsafetyofsofosbuvirplusribavirinforkoreanpatientswithhepatitiscvirusgenotype2infectionaretrospectivemultiinstitutionalstudy |